Literature DB >> 31250756

The Role of Shcbp1 in Signaling and Disease.

Geng-Yuan Zhang1, Zhi-Jian Ma1, Long Wang1, Ruo-Fei Sun1, Xiang-Yan Jiang2, Xu-Juan Yang2, Bo Long1, Hui-Li Ye3, Shu-Ze Zhang1, Ze-Yuan Yu1, Wen-Gui Shi3, Zuo-Yi Jiao1.   

Abstract

Src homolog and collagen homolog (Shc) proteins have been identified as adapter proteins associated with cell surface receptors and have been shown to play important roles in signaling and disease. Shcbp1 acts as a Shc SH2-domain binding protein 1 and is involved in the regulation of signaling pathways, such as FGF, NF-κB, MAPK/ERK, PI3K/AKT, TGF-β1/Smad and β -catenin signaling. Shcbp1 participates in T cell development, the regulation of downstream signal transduction pathways, and cytokinesis during mitosis and meiosis. In addition, Shcbp1 has been demonstrated to correlate with Burkitt-like lymphoma, breast cancer, lung cancer, gliomas, synovial sarcoma, human hepatocellular carcinoma and other diseases. Shcbp1 may play an important role in tumorigenesis and progression. Accordingly, recent studies are reviewed herein to discuss and interpret the role of Shcbp1 in normal cell proliferation and differentiation, tumorigenesis and progression, as well as its interactions with proteins. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Shcbp1; diseases; gliomas; lung cancer; signaling; tumor.

Year:  2019        PMID: 31250756     DOI: 10.2174/1568009619666190620114928

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  8 in total

1.  Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.

Authors:  Ning Wang; Lingye Zhu; Liangxing Wang; Zhifa Shen; Xiaoying Huang
Journal:  Comput Struct Biotechnol J       Date:  2022-06-18       Impact factor: 6.155

2.  SHCBP1 Promotes Papillary Thyroid Carcinoma Carcinogenesis and Progression Through Promoting Formation of Integrin and Collagen and Maintaining Cell Stemness.

Authors:  Houfa Geng; Mengzhe Guo; Wei Xu; Xiu Zang; Tingting Wu; Fei Teng; Yu Wang; Xuekui Liu; Xiuli Wang; Qiang Sun; Jun Liang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-26       Impact factor: 5.555

3.  Construction of a circular RNA-microRNA-messenger RNA regulatory network of hsa_circ_0043256 in lung cancer by integrated analysis.

Authors:  Yongwen Li; Ruifeng Shi; Guangsheng Zhu; Chen Chen; Hua Huang; Min Gao; Songlin Xu; Peijun Cao; Zihe Zhang; Di Wu; Xuanguang Li; Hongyu Liu; Jun Chen
Journal:  Thorac Cancer       Date:  2021-11-21       Impact factor: 3.500

4.  EGF-induced nuclear translocation of SHCBP1 promotes bladder cancer progression through inhibiting RACGAP1-mediated RAC1 inactivation.

Authors:  Hubin Yin; Chen Zhang; Zongjie Wei; Weiyang He; Ning Xu; Yingjie Xu; Tinghao Li; Ke Ren; Youlin Kuang; Xin Zhu; Fangchao Yuan; Haitao Yu; Xin Gou
Journal:  Cell Death Dis       Date:  2022-01-10       Impact factor: 8.469

5.  Effects of Shenkang Pills on Early-Stage Diabetic Nephropathy in db/db Mice via Inhibiting AURKB/RacGAP1/RhoA Signaling Pathway.

Authors:  Fujing Wang; Jia'er Fan; Tingting Pei; Zhuo'en He; Jiaxing Zhang; Liliang Ju; Zhongxiao Han; Mingqing Wang; Wei Xiao
Journal:  Front Pharmacol       Date:  2022-02-11       Impact factor: 5.810

6.  Identification of Recurrent Chromosome Breaks Underlying Structural Rearrangements in Mammary Cancer Cell Lines.

Authors:  Natalie C Senter; Andrew McCulley; Vladimir A Kuznetsov; Wenyi Feng
Journal:  Genes (Basel)       Date:  2022-07-11       Impact factor: 4.141

7.  Long Non-Coding RNA TP53TG1 Upregulates SHCBP1 to Promote Retinoblastoma Progression by Sponging miR-33b.

Authors:  Hongyi Wang; Zhen Zhang; Yue Zhang; Shihai Liu; Li Li
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

8.  SHCBP1 Promotes the Progression of Esophageal Squamous Cell Carcinoma Via the TGFβ Pathway.

Authors:  Chunhong Ren; Zhengbo Zhou; Xiuzhen Wang; Xu Hua; Muping Zou; Xin Zhang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.